Resources
Evidence, insights, and practical guidance for patient engagement
Breast cancer remains one of the most prevalent malignancies worldwide, with an estimated 287,850 new invasive cases and 43,250 breast cancer–related deaths projected in the United States in 2025 (American Cancer Society, 2025). Despite advances in targeted oral therapies for extended adjuvant treatment, real‐world studies find that up to 50% of patients discontinue or skip doses, undermining efficacy (Mayo Clinic, 2024).
Multiple Sclerosis (MS) represents a formidable challenge in healthcare, a chronic, often unpredictable disease of the central nervous system that impacts millions worldwide. Its complex nature demands not just cutting-edge therapies but also robust, sustained patient support to navigate the daily realities of living with the condition.
Medication non-adherence is a $300B issue that can impact the cost of prescription drugs, medical care, and lead to serious health risks. Unfortunately, without greater support, non-adherence can become commonplace especially among patients with chronic disease. But medication non-adherence is more than just skipping a dose or forgetting a refill.
Here’s what today’s pricing development means for pharma brand marketers, patient support teams, innovation leads, access executives, and procurement leadership—and how Medisafe is uniquely positioned to drive higher adherence, long-term engagement, and ultimately better outcomes for those embarking on complex treatment journeys.
For the 133 million Americans who live with a chronic condition, and the 81 million who have two or more conditions, managing medications is more than just taking a pill. It becomes a priority to maintaining good health and the ability to live an active and fulfilling life.
Leading pharmaceutical companies are now using AI to help healthcare providers simplify and streamline the patient experience for specialty medications, which can be difficult to access, adhere to, and afford.
A cure mindset changes everything. That’s the animating force behind our conversation with Beth Dean, CEO of CURE Epilepsy, as we unpack how a parent-founded nonprofit reframed a field long focused on treatments and built a pipeline that backs bold science, supports families, and accelerates breakthroughs.
Medisafe’s real-world data shows that more than half of patients taking the most-prescribed antiplatelet meds have missed 1 to 5+ consecutive doses, leaving some untreated and at a greater risk of thrombosis and other complications.
This article explores how Medisafe’s intelligent patient engagement platforms provide unparalleled value to pharmaceutical executives, from driving adherence to surfacing actionable insights, and how these offerings are setting new standards in digitally enabled patient care. Discover the technologies and trends poised to shape pharma’s next competitive advantage.
This app led to a significant improvement in medication adherence for participants. 93% of patients reported that the app’s medication reminders helped them take their medications on time, a crucial factor in managing chronic conditions like hypertension, diabetes, and heart disease.
